STOCK TITAN

Travere Therapeutics Inc - TVTX STOCK NEWS

Welcome to our dedicated news page for Travere Therapeutics (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Travere Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Travere Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
none
-
Rhea-AI Summary
Mirum Pharmaceuticals and Travere Therapeutics have entered into a definitive agreement for the sale of Travere's bile acid product portfolio. Mirum will acquire Travere's rights to Cholbam® and Chenodal® for $445 million, with $210 million upfront and up to $235 million in potential sales-based milestones. Mirum has secured $210 million in funding to finance the upfront payment. The transaction is expected to close in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
Rhea-AI Summary
Travere Therapeutics, Inc. granted inducement equity grants to three new employees, consisting of 13,750 shares of its common stock. The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.67%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.2%
Tags
Travere Therapeutics Inc

Nasdaq:TVTX

TVTX Rankings

TVTX Stock Data

484.81M
60.60M
0.65%
115.18%
13.93%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
San Diego